Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.8.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Operating Costs and Expenses:      
General and administrative $ 7,467 $ 10,143 $ 8,074
Research and development 18,784 29,109 32,906
Total Operating Costs and Expenses 26,251 39,252 40,980
Loss from Operations (26,251) (39,252) (40,980)
Other Income (Expense):      
Change in fair value of warrant liability 10,738 11,412 (3,811)
Interest income 21 37 6
Total Other Income (Expense) 10,759 11,449 (3,805)
Net Loss (15,492) (27,803) (44,785)
Net Loss Attributable to Non-controlling Interest (318) (548) (1,048)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (15,174) (27,255) (43,737)
Series A Preferred Stock Dividends (6,962) 0 0
Net Loss Attributable to Common Stockholders $ (22,136) $ (27,255) $ (43,737)
Net Loss Per Share - Basic and Dilutive $ (0.18) $ (0.29) $ (0.54)
Weighted average number of shares outstanding during the period - Basic and Dilutive 124,366,059 94,290,436 80,705,692